谷氨酸羧肽酶Ⅱ
前列腺切除术
生化复发
前列腺特异性抗原
医学
泌尿科
单中心
前列腺
前瞻性队列研究
核医学
内科学
癌症
作者
Rui Bernardino,Katherine Lajkosz,Liangjie Yin,Rashid K. Sayyid,Marian S. Wettstein,Harkanwal Randhawa,Jessica Cockburn,Ahmed Sayeed,Rosita Thomassian,Eleftherios P. Diamandis,Ur Metser,Alejandro Berlín,Neil Fleshner
标识
DOI:10.2967/jnumed.124.267877
摘要
In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to better stratify patients who may or may not benefit from a PSMA PET scan. The role of the free-to-total prostate-specific antigen (PSA) ratio (FPSAR) in posttreatment prostate cancer, specifically in the PSMA PET/CT era, remains unknown. Our aim in this study was to determine the association of FPSAR in patients referred for
科研通智能强力驱动
Strongly Powered by AbleSci AI